An Open-label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-infected Adolescents, ≥ 12 to < 18 Years of Age Who Weigh at Least 25 kg

This is a Phase IIIb, single-arm, open-label, multi-center assessment of DTG/3TC in approximately 30 HIV-1 infected, treatment-naive adolescents with plasma HIV-1 RNA between 1,000 and ≤500,000 c/mL. All enrolled participants will receive an open-label, two-drug regimen of DTG/3TC for 48 weeks. Participants who successfully complete 48 weeks of treatment may enter the study Extension Phase for an additional 96 weeks. At the end of the study, participants who continue to receive benefit from DTG/3TC and for whom these medications are not locally accessible, will have access to medication until it is available locally.